SCHEMBL2650113

SCHEMBL2650113

O=C(O)CCNC(=O)c1ccc(C(NC(=O)Nc2cccc(Cl)c2)c2ccc(C3=CCCCC3)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 11/20 0.57
GIPR P48546 9/20 0.57
GLP1R P43220 4/20 0.57
DGAT1 O75907 1/20 0.47
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
ALDH1A1 P00352 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SERPINE1 P05121 1/20 0.41
MCHR1 Q99705 1/20 0.41
ADCY6 O43306 1/20 0.41
ADCY3 O60266 1/20 0.41
ADCY9 O60503 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2652200 0.92 GCGR (0.67) GCGRGIPRGLP1RNPC1RAB9A
SCHEMBL2651789 0.90 GCGR (0.49) GCGRGIPRGLP1RRAB9AALDH1A1
SCHEMBL2651200 0.90 GCGR (0.49) GCGRGIPRGLP1RNPC1RAB9A
SCHEMBL2651843 0.90 GCGR (0.49) GCGRGIPRGLP1RMAPTADCY6
SCHEMBL6752839 0.90 GCGR (0.49) GCGRGIPRGLP1RDGAT1NPC1
SCHEMBL2651224 0.90 GCGR (0.49) GCGRGIPRGLP1RNPC1RAB9A
SCHEMBL2650187 0.89 GCGR (0.54) GCGRGIPRGLP1RMAPTSMN1; SMN2
SCHEMBL6750344 0.88 GCGR (0.49) GCGRGIPRGLP1RADCY6ADCY3
SCHEMBL2650683 0.88 GCGR (0.49) GCGRGIPRGLP1RNPC1RAB9A
SCHEMBL2651030 0.88 GCGR (0.48) GCGRGIPRGLP1RMCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127560-A1 Glucagon antagonists/inverse agonists MADSEN PETER (DK) 2004-07-01 US claimed
US-6706744-B2 HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS NOVO NORDISK A/S (DK) 2004-03-16 US claimed
US-20030065031-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-04-03 US claimed
WO-2002040444-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-05-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127560-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885GLP1R 1/4885
US-20030065031-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885GLP1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.